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RESEARCH AND THEORY
Effects of Integrated Care on Disease-Related 
Hospitalisation and Healthcare Costs in Patients  
with Diabetes, Cardiovascular Diseases and Respiratory 
Illnesses: A Propensity-Matched Cohort Study  
in Switzerland
Carola A. Huber*, Oliver Reich*, Mathias Früh* and Thomas Rosemann†
Background: There is an ongoing discussion on the further promotion of integrated care models in many 
healthcare systems. Only a few data, which examine the effect of integrated care models on medical 
expenditures and quality of care in chronically ill patients, exist.
Aims: To investigate the effect of integrated care models on disease-related hospitalisations as a  quality 
indicator and healthcare costs in patients with either diabetes, cardiovascular diseases or respiratory 
illnesses.
Methods: A propensity-matched retrospective cohort study based on a large Swiss health  insurance 
 database (2012–2013) was performed for three chronic patient groups (diabetes, cardiovascular 
diseases, respiratory illnesses), who were enrolled in an integrated care model and compared to individuals 
in a standard care model. Multivariate regression models were applied to estimate the effect of integrated 
care models on disease-related hospitalisations and healthcare costs.
Results: The matched cohorts included a total of 12,526 patients with diabetes, 71,778 with cardiovas-
cular diseases and 17,498 with respiratory illnesses, in which each one half was enrolled in integrated care 
models and the other half in standard care models. Diabetes and cardiovascular patients with integrated 
care models had a significantly lower probability of disease-related hospitalisation compared to those 
with standard care models (p < 0.01). Healthcare costs were statistically significant lower in all three 
patient groups with integrated care, but with the highest effect in patients with diabetes (Swiss francs 
(CHF) −778).
Conclusions: Integrated care may provide an effective strategy to improve the quality of care and to 
reduce healthcare costs in chronically ill patients. Study findings intend to contribute to the ongoing 
political discussion on integrated care and provide evidence for improved and more effective care of 
patients with chronic diseases.
Keywords: integrated care; hospitalization; costs; chronic diseases
Introduction
Switzerland has almost 20 years of experience in the 
 development of integrated care models [1] and provides a 
wide range of insurance plans. In 2013 nearly 60% of the 
Swiss population were enrolled in integrated care models [2]. 
But despite this high percentage of enrolees, there is 
an ongoing discussion on the further promotion of inte-
grated care models in the Swiss healthcare system. The reason 
for this discussion is the existence of different types 
of integrated care models. Contracted capitated models 
suggest the greatest potential for efficient care coordina-
tion, but only about a quarter of all insured persons are 
enrolled in this type of health plan [3]. Overall, integrated 
care models are seen as possible interventions to improve 
the quality in healthcare use and to reduce medical 
expenditures, especially in patients with chronic diseases. 
However, there is little international as well as national 
evidence on the improved healthcare quality and the cost-
effectiveness of managed care models among chronically 
ill patients. A recent published meta-review suggests a 
beneficial effect of integrated care programmes on some 
outcomes, including hospital admissions and quality of 
care, in adults affected by chronic conditions [4]. A few 
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reviews reported reduced costs [4]. Since the existing stud-
ies were often performed in fully integrated healthcare 
settings (e.g. US health maintenance organisations), the 
results are not directly transferable to other healthcare 
settings. In Switzerland, only a few studies investigated 
the effect of integrated care on medical expenditures and 
healthcare use. These suggested an economic efficiency of 
selected integrated care models in different Swiss health-
care settings, exist [5–10]. Furthermore, little is known 
about the effect of integrated care on the quality of care, 
especially in patients with chronic diseases [10, 11]. The 
implementation of integrated care exerts great poten-
tial for coordination advantages and is, thus, particularly 
useful for patient groups suffering from highly prevalent 
chronic diseases. There is strong evidence that diabetes 
mellitus, cardiovascular diseases and respiratory illnesses 
are one of the most prevalent and costly chronic diseases 
worldwide [12–14]. Chronically ill patients have a high 
probability to be hospitalised and to incur high medical 
costs. The management of these patient groups can be 
seen as an effective strategy to avoid hospitalisations and 
to reduce healthcare costs.
This study aimed to assess the impact of integrated care 
models on hospital admissions and to determine potential 
cost reductions from integrated care in patients affected 
with highly prevalent chronic diseases including diabe-
tes mellitus, cardiovascular diseases and respiratory ill-
nesses. Using a propensity-matched retrospective cohort 
of patients with diabetes, cardiovascular diseases and res-
piratory illnesses, we compared the probability of disease-
related hospitalisation, reflecting quality of care, and the 
incurred healthcare costs after 1 year between patients 
who were and were not enrolled in integrated care models.
Methods
Study design and population
We performed a cohort study embedded in insurance 
claims data from the Helsana health insurance group. 
Helsana is the leading health insurer in Switzerland cov-
ering about 1.2 million mandatory insured persons. The 
patient-level linked database included longitudinal infor-
mation on sociodemographics, health insurance status, 
prescribed drugs, healthcare utilisation and its associated 
costs. Data also included information on health insurance 
models. Insured persons can choose between a stand-
ard care model, which allows the freedom of choice and 
unlimited access to physicians in the outpatient setting, 
and an integrated care model, but receive in return of it 
the benefit of premium reduction. In this study we used 
data of patients continuously enrolled between 2012 and 
2013 in contracted integrated care model with capitation. 
In contracted models with capitation, a network of phy-
sicians corporates with the health insurer [6]. These net-
works comprise either a group of independent individual 
(general) practitioners or a Health Maintenance Organi-
sation. The network assumes collective responsibility for 
a financial budget which consists of per capita funding 
calculated by the health insurer. Within this remunera-
tion by capitation scheme, the network members  provide 
healthcare for the contractually insured persons for 
1 year. However, this budget is rather virtual than paid per 
se since the providers are paid by the nationwide fee-for-
service scheme and do not receive a defined periodic pay-
ment. In case the virtual budget falls below the negotiated 
limit after the year, the remaining difference will be split 
between the network and the health insurer. Otherwise, if 
the budget is exceeded, the negative difference will be also 
divided. Besides the mentioned economic responsibility, 
the capitation model has in the first instance a high medi-
cal responsibility for the whole treatment process, primar-
ily regarding the interface management between the dif-
ferent specialists and gatekeepers in the outpatient setting 
as well as between the different (inpatient) institutions.
Overall, there are two important aspects regarding 
coordinated and integrated care. The first one is the gate-
keeping aspect, which refers to the coordination at the 
beginning of the treatment process. Patients enrolled in 
an integrated care model have to initially refer to their 
chosen general practitioner, when they seek medical aid. 
The second one is the coordination aspect during the 
treatment process, which appears after the entry into the 
healthcare system by further referrals to specialists or 
hospitals.
Our cohort includes men and women aged 18 years 
or older who were identified as patients with diabetes, 
cardiovascular diseases and respiratory illnesses in 2012. 
Patients with chronic diseases were identified by an inpa-
tient International Classification of Diseases, Version 10, 
German Modification, diagnosis or by the ‘WHO 
Anatomical Therapeutic Chemical code’ of prescribed 
drugs (outpatient setting). A patient was, therefore, iden-
tified as having diabetes when the person either was 
diagnosed with diabetes by a hospital discharge record 
according to the International Classification of Diseases, 
Version 10, classification system (E10–E14) or had been 
prescribed any anti-diabetic drug (WHO Anatomical 
Therapeutic Chemical code: A10) in the outpatient set-
ting in 2012. Using prescribed drug data as proxies for 
diagnoses from the outpatient setting is considered a 
valid approach in the literature [15–18]. Our classification 
system for the identification of patients with diabetes as 
well as with cardiovascular diseases and respiratory ill-
ness is described in Appendix Table A1. Since patients 
enrolled in an integrated care model may differ in base-
line characteristics from patients in a standard care model, 
we performed propensity score matching for each patient 
group with chronic disease to balance observed covariates 
and to adjust for confounding. Propensity score match-
ing is increasingly being used to reduce the impact of 
selection bias when estimating causal treatment effects 
using observational data [19]. To calculate the propensity 
score for each patient group, we fitted a logistic regres-
sion model in which the outcome was the probability 
of enrolment in an integrated care model, predicted by 
patient’s age, sex, region of residence, type of cost-shar-
ing (deductibles: low (Swiss francs (CHF) 300/500) versus 
high (Swiss francs (CHF) 1000–2500), number of hospital 
days in the year before and comorbidity. Patients’ comor-
bidity was measured by an updated Chronic Disease Score. 
The Chronic Disease Score is a proxy measure of severity 
of chronic morbidity, based on dispending pharmacy data 
validated in a Swiss population and is divided into five 
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levels (‘low’ (level 1); ‘middle’ (levels 2 and 3); ‘high’ 
(levels 4 and 5)) [20]. By using patients’ individual propensity 
score, patients enrolled in an integrated care model were 
matched to an equal number of those with a standard care 
model, who had the closest estimates of propensity score 
(nearest neighbour method, 1:1 matching). The adequacy 
of the matching was checked by two approaches: visual 
inspection and calculating efficiency measures [21, 22]. 
For visual inspection, we displayed the distribution of 
propensity score and performed histograms of propen-
sity scores before and after matching. For the numerical 
inspection, we calculated measures which reflect the effec-
tiveness of the propensity score matching: (1) summary 
of balance for all (original) data, (2) summary of balance 
for matched data and (3) percent balance improvement. 
The first and second steps provide the mean differences in 
the density of the covariates for the treatment (integrated 
care) and control group (standard care model) before and 
after matching (percent balance). The last step gives the 
mean difference by comparing the mean difference for all 
data with the mean difference for matched data (percent 
balance improvement).
Outcomes
Disease-related hospitalisations in the follow-up year (2013) 
were defined for all three patient groups as having at least 
one given disease-related diagnosis at hospital discharge in 
2013 according to the International Classification of Dis-
eases, Version 10, classification system. For patients identi-
fied with diabetes in 2012, each hospitalisation associated 
with diabetes in 2013 was taken into account. Furthermore, 
common complications in patients with diabetes related to 
ischaemic heart diseases, cerebrovascular diseases, renal 
failure, glomerular disorders in diabetes, diabetic cataract, 
diabetic retinopathy, atherosclerosis, diabetic peripheral 
angiopathy, diabetic mononeuropathy and diabetic poly-
neuropathy were included. Hospitalisations related to car-
diovascular diseases were defined as hospitalisations caused 
by hypertensive diseases, ischaemic heart diseases, pulmo-
nary heart disease and diseases of pulmonary circulation, 
paroxysmal tachycardia, atrial fibrillation and flutter, other 
cardiac arrhythmias, heart failure, cerebrovascular diseases 
and diseases of arteries, arterioles and capillaries. Follow-
ing complications in patients with respiratory illnesses 
were considered: simple and mucopurulent chronic bron-
chitis, unspecified chronic bronchitis, emphysema, other 
chronic obstructive pulmonary disease, asthma, status 
asthmaticus and bronchiectasis. If one of these complica-
tions in each patient group (diabetes, cardiovascular dis-
eases, respiratory illnesses) was recorded as the primary 
or secondary diagnosis in the inpatient claims, the hospi-
talisation was specified as disease-related. The classification 
for the three chronic groups by the International Classifica-
tion of Diseases, Version 10, codes is shown in Appendix 
Table A2.
Total healthcare costs were defined as the sum of out-
patient and inpatient costs per patient/year (2013). 
Outpatient costs included payments for office-based phy-
sician visits, hospital outpatient visits, paramedical visits, 
prescription drugs, laboratory tests and medical devices. 
Inpatient costs included payments for hospitalisations, 
rehabilitation, nursing and emergency transport services. 
Costs associated with hospitalisation such as drugs or 
medical drugs were routinely included in the charge for 
these hospitalisations.
Statistical analysis
Based on the propensity score-matched sample, we ana-
lysed the matched pairs using frequency tables. Descrip-
tive results are given as number (percentage) of patients 
for categorical variables and as mean values with stand-
ard deviation for numeric variables. Logistic regression 
models were applied to estimate the effect of integrated 
care on disease-related hospitalisations for all three 
patient groups. Multiple linear regression analysis was 
performed to determine the impact of integrated care on 
healthcare costs among chronically ill patients. Given the 
skewed nature of the cost distribution, we used gener-
alised linear models with negative binomial distribution 
and with linear link function, which provided absolute 
values in Swiss Francs (CHF) as estimates. We adjusted 
the models for age, sex, region of residence, deductibles, 
comorbidity and the number of hospitalised days in 
the year before. All analyses were performed using the 
 statistical program ‘R’.
Results
We identified a total of 36,532 patients with diabetes, 
186,986 with cardiovascular diseases and 45,364 with 
respiratory illnesses from source population at baseline. 
Population characteristics before matching are shown in 
Appendix Table A3. After applying propensity match-
ing, we included 12,526 patients with diabetes, 71,778 
with cardiovascular diseases and 17,498 with  respiratory 
illnesses. Results from calculating covariate balancing 
before and after matching showed that the adequacy 
of the matching was given (Appendix Tables A4–A6; 
Figures A1–A2). In the matched samples, differences 
in the distribution of the covariates between the patient 
group with integrated care models (treated group) and 
those with standard care models (control group) were 
much smaller for most of the variables. The matching 
considerably improved their balance. Population charac-
teristics from the propensity-matched sample for all three 
patient groups are shown in Table 1. In each patient 
group, the number of persons with an integrated care 
model was equal to the number of persons with a stand-
ard care model. The patient group with diabetes consisted 
of a higher proportion of men (56%), included about 58% 
of patients aged between 65 and 84 years, and the major-
ity had a high level of comorbidity (levels 4 and 5: 57%). 
Among patients with cardiovascular diseases, the propor-
tion of men was slightly lower (47%), the mean age was 68 
years and more than half had a comorbidity level of 3 or 
4 (54%). Patients with respiratory illnesses included about 
42% of patients aged younger than 55 years, more than 
half were women (56%) and most had middle to high 
comorbidity level (50%).
The proportions in population characteristics between 
persons with integrated care models and those with 
standard care models were approximately balanced after 
matching (Table 2).
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Characteristic Patients with diabetes  
n = 12,526
Patients with cardiovascular 
diseases n = 71,778
Patients with respiratory 
illnesses n = 17,498
n (%) n (%) n (%)
Population characteristics (2012)
Male 7043 (56.2) 33,716 (47.0) 7686 (43.9)
Mean age (sd) 67.1 (12.7) 67.9 (13.5) 56.7 (18.6)
Age group (years)
 18–44 677 (5.4) 4063 (5.7) 4848 (27.7)
 45–54 1236 (9.9) 7307 (10.2) 2551 (14.6)
 55–64 2683 (21.4) 13,894 (19.4) 2988 (17.1)
 65–74 4082 (32.6) 21,536 (30.0) 3797 (21.7)
 75–84 3167 (25.3) 18,823 (26.2) 2629 (15.0)
 ≥85 681 (5.4) 6155 (8.6) 685 (3.9)
Region of residence
 Lake Geneva 823 (6.6) 3666 (5.1) 1986 (11.4)
 Mittelland 2586 (20.7) 14,745 (20.5) 3768 (21.5)
 Northwest 3240 (25.9) 17,571 (24.5) 3919 (22.4)
 East 2628 (21.0) 14,982 (20.9) 2808 (16.1)
 Ticino 10 (0.1) 66 (0.1) 26 (0.2)
 Central 465 (3.7) 2727 (3.8) 691 (4.0)
 Zurich 2774 (22.2) 18,021 (25.1) 4300 (24.6)
Health insurance status
 Care model
  Standard care model 6263 (50.0) 6263 (50.0) 6263 (50.0)
  Integrated care model 6263 (50.0) 6263 (50.0) 6263 (50.0)
 Deductible
  High (>CHF500) 608 (4.9) 7575 (10.6) 2521 (14.4)
  Low (CHF300/500) 11,918 (95.2) 64,203 (89.5) 14,977 (85.6)
Chronic Disease Score
 Mean chronic disease score (sd) 7053 (5679.7) 5048 (4808.9) 5702 (5366.3)
 Level 1 (0–999) 623 (5.0) 11,757 (16.4) 3437 (19.6)
 Level 2 (1000–2499) 2710 (21.6) 12,977 (18.1) 2707 (15.5)
 Level 3 (2500–4999) 2102 (16.8) 17,126 (23.9) 3539 (20.2)
 Level 4 (5000–9999) 4234 (33.8) 21,347 (29.7) 5169 (29.4)
 Level 5 (≥10,000) 2857 (22.8) 8570 (11.4) 2646 (15.1)
Hospitalisation (2011) 2349 (18.8) 12,049 (16.8) 2749 (15.7)
No. of hospitalised days (2011)
 Mean days (sd) 3.2 (12.2) 2.4 (9.7) 2.2 (9.4)
 0–3 days 10,604 (84.7) 62,483 (87.1) 15,440 (88.2)
 4–10 days 969 (7.7) 4826 (6.7) 1149 (6.6)
 >10 days 953 (7.6) 4469 (6.2) 909 (5.2)
Table 1: Patients’ characteristics by chronic disease after propensity matching. 
sd, standard deviation.
Overall, 19% of persons enrolled in integrated care models 
and 21% of controls (with standard care model) had at least 
one diabetes-related hospitalisation (total) in the following 
year among the patient group with diabetes (Table 3).
In the diabetes cohort, renal failure (6.1 and 6.0% of 
all patients, respectively) and ischaemic heart disease 
(5.8 and 6.1% of all patients, respectively) were the most 
prevalent diabetes-related complications. Hypertensive 
disease was the most frequent cause of cardiovascular 
disease-related hospitalisation in the cohort with car-
diovascular diseases (12 and 13% of all patients, respec-
tively). Approximately 7% of the patients with respiratory 
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Characteristic Diabetes Cardiovascular diseases Respiratory illnesses
With ICM  
n = 6263
With SCM  
n = 6263
With ICM  
n = 35,889
With SCM  
n = 35,889
With ICM  
n = 8749
With SCM  
n = 8749
n (%) n (%) n (%) n (%) n (%) n (%)
Population characteristics (2012)
Male 3507 (56.0) 3536 (56.5) 16,913 (47.1) 16,803 (46.8) 3770 (43.1) 3916 (44.8)
Mean age (sd) 67.1 (12.8) 67.1 (12.6) 68.0 (13.5) 67.8 (13.5) 57.1 (18.9) 56.3 (18.3)
Age group (years)
 18–44 355 (5.7) 322 (5.1) 2071 (5.8) 1992 (5.6) 2434 (27.8) 2414 (27.6)
 45–54 615 (9.8) 621 (9.9) 3508 (9.8) 3799 (10.6) 1186 (13.6) 1365 (15.6)
 55–64 1264 (20.2) 1419 (22.7) 6701 (18.7) 7193 (20.0) 1398 (6.0) 1590 (18.2)
 65–74 2073 (33.1) 2009 (32.1) 11,024 (30.7) 10,512 (29.3) 1986 (22.7) 1811 (20.7)
 75–84 1634 (26.0) 1536 (24.5) 9594 (26.7) 9229 (25.7) 1390 (15.9) 1239 (14.2)
 ≥85 325 (5.2) 356 (5.7) 2991 (8.3) 3164 (8.8) 355 (4.1) 330 (3.8)
Region of residence
 Lake Geneva 407 (6.5) 413 (6.6) 1815 (5.1) 1866 (5.2) 952 (10.9) 1032 (11.8)
 Mittelland 1297 (20.7) 1290 (20.6) 7340 (20.5) 7393 (20.6) 1877 (21.5) 189 (21.6)
 Northwest 1636 (26.1) 1603 (25.6) 8880 (24.7) 8685 (24.2) 1992 (22.8) 1925 (22.0)
 East 1307 (20.9) 1321 (21.1) 7506 (20.9) 7465 (20.8) 1442 (16.5) 1365 (15.6)
 Ticino 5 (0.1) 6 (0.1) 33 (0.1) 36 (0.1) 13 (0.2) 17 (0.2)
 Central 235 (3.8) 232 (3.7) 1370 (3.8) 1364 (3.8) 354 (4.1) 341 (3.9)
 Zurich 1376 (22.0) 1397 (22.3) 8945 (27.9) 9080 (25.3) 2119 (24.2) 2179 (24.9)
Health insurance status
 Deductible
  High (>CHF500) 311 (5.0) 297 (4.7) 3844 (10.7) 3731 (10.4) 1276 (14.6) 1245 (14.2)
  Low (CHF300/500) 5952 (95.0) 5966 (95.3) 32,045 89.3) 32,158 (89.6) 7473 (85.4) 7504 (85.8)
Chronic Disease Score
  Mean chronic disease 
score (sd)
7141 (5860.7) 6966 (5491.9) 5122 (4928.4) 4975 (4685.2) 5844 (5560.4) 5561 (5161.5)
 Level 1 (0–999) 302 (4.8) 321 (5.1) 5873 (16.4) 5884 (16.4) 1660 (19.0) 1777 (20.3)
 Level 2 (1000–2499) 1326 (21.2) 1384 (22.1) 6396 (17.8) 6585 (18.4) 1330 (15.2) 1377 (15.7)
 Level 3 (2500–4999) 1061 (16.9) 1041 (16.6) 8544 (23.8) 8581 (23.9) 1782 (20.4) 1757 (20.1)
 Level 4 (5000–9999) 2129 (34.0) 2105 (33.6) 10,686 (29.8) 10,659 (29.7) 2638 (30.2) 2531 (28.9)
 Level 5 (≥10,000) 1445 (23.1) 1412 (22.6) 4390 (12.2) 4180 (11.7) 1339 (15.3) 1307 (14.9)
Hospitalisation (2011) 1217 (19.4) 1132 (18.1) 6512 (18.1) 5537 (15.4) 1376 (15.7) 1373 (15.7)
No. of hospitalised days (2011)
 Mean days (sd) 3.2 (12.4) 3.1 (12.0) 2.6 (10.4) 2.2 (8.9) 2.3 (10.3) 2.0 (8.4)
 0–3 days 5284 (84.4) 5320 (84.9) 30,896 (86.1) 31,587 (88.0) 7715 (88.2) 7725 (88.3)
 4–10 days 494 (7.9) 475 (7.6) 2678 (7.5) 2148 (6.0) 583 (6.7) 566 (6.5)
 >10 days 485 (7.7) 468 (7.5) 2315 (6.5) 2154 (6.0) 451 (5.1) 458 (5.2)
Table 2: Patients’ characteristics by chronic disease and care model (integrated vs standard) after propensity matching.
ICM, integrated care model; SCM, standard care model; sd, standard deviation.
illnesses were hospitalised caused by a respiratory-related 
illness in the follow-up year.
Table 4 shows the mean total healthcare costs for 
patients with and without integrated care models among 
all three patient groups. The cost difference between 
patients enrolled in integrated care models and those 
with standard care models amounted to CHF 1064 per 
patient/year in the diabetes cohort, CHF 680 in the cohort 
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Table 3: Disease-related hospitalisation frequencies by chronic disease and care model (integrated vs standard) after 
propensity matching.
ICM, integrated care model; SCM, standard care model.
Hospitalisation Diabetes Cardiovascular diseases Respiratory illnesses
With ICM  
n = 6263
With SCM  
n = 6263
With ICM  
n = 35,889
With SCM  
n = 35,889
With ICM  
n = 8749
With SCM 
n = 8749
n (%) n (%) n (%) n (%) n (%) n (%)
Diabetes related cause of hospitalisation (total) 1194 (19.1) 1298 (20.7)
 Diabetes mellitus 1135 (18.1) 1229 (19.6)
 Renal failure 383 (6.1) 377 (6.0)
 Retinal disorder and cataract 12 (0.2) 24 (0.4)
 Ischaemic heart disease 366 (5.8) 382 (6.1)
 Cerebrovascular disease 74 (1.2) 83 (1.3)
 Atherosclerosis 126 (2.0) 147 (2.4)
 Diabetic peripheral angiopathy 39 (0.6) 52 (0.8)
 Diabetic monoeuropathy 1 (0.02) 1 (0.02)
 Diabetic polyneuropathy 60 (1.0) 67 (1.1)
Cardiovascular disease-related cause of 
hospitalisation (total)
5273 (14.7) 5508 (15.4)
 Hypertensive disease 4428 (12.3) 4673 (13.0)
 Ischaemic heart disease 1537 (4.3) 1566 (4.4)
  Pulmonary heart disease and diseases of 
pulmonary circulation
245 (0.7) 273 (0.8)
 Other form of heart diseases 1655 (4.6) 1706 (4.8)
 Cerebrovascular disease 339 (0.9) 367 (1.0)
  Atherosclerosis, aortic aneurysm and dissection 
and other aneurysm and dissection
509 (1.4) 589 (1.6)
Peripheral vascular disease, unspecified 54 (0.2) 46 (0.1)
 Arterial embolism and thrombosis 54 (0.2) 72 (0.2)
Respiratory illness-related cause of 
hospitalisation (total)
602 (6.9) 594 (6.8)
 Simple and mucopurulent chronic bronchitis 4 (0.1) 3 (0.03)
 Unspecified chronic bronchitis 12 (0.1) 9 (0.1)
 Emphysema 9 (0.1) 6 (0.1)
  Other chronic obstructive pulmonary disease 419 (4.8) 404 (4.6)
 Asthma 174 (2.0) 194 (2.2)
 Status asthmaticus 2 (0.02) 5 (0.1)
 Bronchiectasis 14 (0.2) 7 (0.1)
Hospitalisation Diabetes Cardiovascular diseases Respiratory illnesses
Total
With ICM 
n = 6263
With SCM 
n = 6263 Total
With ICM  
n = 35,889
With SCM  
n = 35,889 Total
With ICM  
n = 8749
With SCM  
n = 8749
CHF CHF CHF CHF CHF CHF CHF CHF CHF
Total healthcare 
costs (mean, 
standard deviation)
10,000 
(14379.7)
9466 
(13418.6)
10,530 
(15263.0)
7842 
(13063.5)
7502 
(12186.2)
8182 
(13877.4)
7679 
(14664.5)
7428 
(13164.8)
7929 
(16021.2)
Table 4: Total healthcare costs by chronic disease and care model (integrated vs standard) after propensity matching.
ICM, integrated care model; SCM, standard care model.
with cardiovascular diseases and CHF 501 in the respira-
tory illnesses cohort.
Table 5 presents the results of the multivariate logistic 
regression models estimating the effect of integrated care 
(at baseline: 2012) on disease-related hospitalisations (at 
follow-up: 2013) for each cohort. After adjusting for soci-
odemographics, deductibles, comorbidity and previous 
hospitalisation, a significant effect of integrated care on 
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disease-related hospitalisation could be observed among 
patients with diabetes (Odds Ratio: 0.87; 95% confidence 
interval: 0.79–0.95). For the cardiovascular diseases 
cohort, patients enrolled with an integrated care model 
had a lower risk of being hospitalised caused by a cardio-
vascular diseases than patients with a standard care model 
(Odds Ratio: 0.92, 95% confidence interval: 0.88–0.96). 
There was no significant difference in the probability of 
hospitalisation between patients with an integrated care 
model and patients with a standard care model among 
patients with respiratory illnesses. In all three patient 
groups, men, older patients and patients with higher 
chronic disease scores and higher number of hospitalised 
days in the previous year were significantly more likely 
to have a disease-related hospitalisation in the following 
year. There also seemed to be vast regional variations in 
the probability to be hospitalised.
Table 6 shows the adjusted mean cost differences between 
enrolees in integrated care models and those enrolled in 
standard care models for each patient cohort, controlled 
for sociodemographics and morbidity indicators. The total 
healthcare costs were almost CHF 780 lower in patients with 
integrated care models (coefficient: −777.8, 95% confidence 
interval: −1040.8 to −516.5) compared with patients without 
integrated care models in the diabetes cohort.
The adjusted mean healthcare costs were also esti-
mated for patients with cardiovascular diseases and those 
with respiratory illnesses. For the cardiovascular dis-
eases cohort, the cost difference between patients with 
and without integrated care models amounted to about 
CHF 440 (coefficient: −441.3, 95% confidence interval: 
−527.3 to −355.6), and for the respiratory illnesses cohort, 
approximately CHF 220 (coefficient: −217.9, 95% con-
fidence interval: −340.2 to −96.6). The cost difference 
increased substantially with age, severity of comorbidity 
and the number of hospitalised days in the previous year 
in all three patient groups.
Discussion
In this propensity-matched cohort analysis of a large health 
insurance database in Switzerland we found a substantial 
effect of integrated care on medical expenditures and dis-
ease-related hospitalisations reflecting quality of care in 
patients suffering from highly prevalent chronic diseases.
The first major finding of our study was that the enrol-
ment in an integrated care model predicts a significantly 
decreased probability of future disease-related hospitali-
sation, reflecting quality of care, among patients with dia-
betes and cardiovascular diseases, compared with patients 
enrolled in a standard care model. A difference in hospitali-
sation risk among patients with respiratory illnesses could 
not be proved. These results are in line with a recently 
published meta-review from Martínez-González et al. [4]. 
Despite remarkable heterogeneity in the methodological 
quality of the included reviews, the authors found positive 
effects of integrated care programmes regarding hospital 
admissions and readmissions among patients with chronic 
heart failure and diabetes, and only little evidence on ben-
eficial effects regarding guideline adherence for patients 
with chronic obstructive pulmonary disease. We assume 
that some elements of the concept of ‘integrated care’ (e.g. 
guideline-based treatment) have already been stronger 
implemented in the care of diabetes and cardiovascular 
diseases than in chronic obstructive pulmonary disease 
and asthma in the Swiss general practice. Furthermore, 
our results underline findings from interventions studies 
showing that a multicomponent guide for chronic illness 
leads to better intermediate outcomes in chronically ill 
patients. For example, a systematic US review suggested 
that healthcare organisations, which have used a multi-
component template for chronic illness management 
(the so-called ‘Chronic Care Model’), improve the qual-
ity of patient care and lead to better health outcomes in 
chronically ill patients [23]. Consistent with US findings, 
a recent national study could show an improved diabetes 
management from patients’ perspective in Chronic Care 
Model-orientated managed care organisations compared 
to usual primary care [24]. However, only a few compa-
rable national studies examining the effect of integrated 
care on outcomes such as disease-related hospitalisations, 
reflecting quality of care, are available. One study sug-
gested that patients in managed care health plans had a 
higher rate of potentially inappropriate medication use, 
considered as quality proxy, and also a higher risk to be 
hospitalised [10]. A federal report could show that outpa-
tient hospital visits caused by trivial disorders were lower 
in patients enrolled in contracted integrated care models 
with capitation [25].
The second finding of our study was that integrated care 
reduces healthcare costs up to 10% in all three patient 
groups with chronic diseases, but with highest impact in 
patients with diabetes. Although the international evi-
dence for cost-effectiveness is weak [4], some national 
studies could find an association between integrated 
care models and reduced costs. So our finding are in line 
with previous studies conducted in the Swiss healthcare 
system, which reported a cost reduction between about 
10 and 20% [5, 6]. However, these studies investigated 
the cost-effectiveness for the whole population and did 
not differentiate between the most prevalent chronic 
diseases. Since chronic diseases, such as diabetes, cardio-
vascular diseases and respiratory illnesses, are frequently 
occurring and cost-intensive for the healthcare system, 
integrated care models may provide an effective strategy 
to improve the quality of care and to reduce healthcare 
costs in chronically ill patients. Our study findings contrib-
ute to the ongoing political discussion on integrated care 
and provide evidence for an improved and more effective 
care of patients with chronic diseases. In this context it is 
also important to stress the fact that integrated care mod-
els in our study were defined as a general practitioner- 
centred model or Health Maintenance Organisation model, 
in which the coordinating provider compulsorily coordi-
nates the medical care during the treatment process. In 
view of the fact that the implementation of guidelines is 
not standard in Swiss general practice, it is assumed that 
the corresponding physicians used in varying degrees in 
evidence-based guidelines in the treatment of chronic 
diseases. Thus, our results suggest that this organisational 
structure in healthcare management is already able to 
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Characteristic Hospitalisation (2013)
Diabetes Cardiovascular diseases Respiratory illnesses
Odds ratio
95% confidence 
interval Odds ratio
95% confidence 
interval Odds ratio
95% confidence 
interval
Population characteristics 
Gender
 Male 1.00 1.00 1.00
 Female 0.79*** 0.72–0.87 0.75*** 0.72–0.78 0.64*** 0.57–0.73
Age group (years)
 18–44 1.00 1.00 1.00
 45–54 1.49* 1.06–2.10 2.26*** 1.84–2.78 1.99*** 1.37–2.89
 55–64 1.90*** 1.39–2.60 3.42*** 2.83–4.14 4.31*** 3.12–5.96
 65–74 2.47*** 1.82–3.36 5.11*** 4.24–6.16 6.54*** 4.80–8.92
 75–84 3.57*** 2.62–4.85 7.25*** 6.01–8.73 7.15*** 5.21–9.82
 ≥85 5.11*** 3.64–7.16 10.45*** 8.62–12.65 9.19*** 6.41–13.17
Region of residence
 Lake Geneva 1.00 1.00 1.00
 Mittelland 1.91*** 1.49–2.44 2.11*** 1.84–2.43 1.75*** 1.27–2.40
 Northwest 2.22*** 1.74–2.83 2.53*** 2.21–2.91 2.12*** 1.55–2.90
 East 2.21*** 1.73–2.83 2.41*** 2.09–2.77 2.02*** 1.46–2.79
 Ticino 6.62** 1.84–23.78 1.82 0.89–3.71 2.85 0.77–10.60
 Central 1.90*** 1.37–2.64 2.20*** 1.85–2.62 1.67* 1.07–2.62
 Zurich 1.93*** 1.50–2.46 2.34*** 2.04–2.69 2.10*** 1.54–2.87
Health insurance status
 Care model
  Standard care model 1.00 1.00 1.00
  Integrated care model 0.87** 0.79–0.95 0.92*** 0.88–0.96 0.95 0.84–1.07
 Deductible
  Low (CHF 300/500) 1.00 1.00 1.00
  High (>CHF500) 0.89 0.70–1.13 0.79*** 0.73–0.86 0.56*** 0.42–0.75
Chronic Disease Score
  Level 1 (0–999) 1.00 1.00 1.00
  Level 2 (1000–2499) 1.33 0.96–1.84 1.25*** 1.14–1.36 1.15 0.81–1.63
  Level 3 (2500–4999) 1.66** 1.20–2.32 1.49*** 1.37–1.61 1.51** 1.11–2.05
  Level 4 (5000–9999) 2.33*** 1.69–3.20 2.02*** 1.87–2.18 1.93*** 1.44–2.58
  Level 5 (≥10,000) 3.51*** 2.55–4.84 2.92*** 2.68–3.18 3.05*** 2.264–4.12
No. of hospitalised days (2011)
 0–3 days 1.00 1.00 1.00
 4–10 days 1.28** 1.10–1.50 1.47*** 1.37–1.59 1.77*** 1.46–2.15
 >10 days 1.92*** 1.66–2.23 1.88*** 1.75–2.02 2.66*** 2.22–3.19
Table 5: Prediction of disease-related hospitalisation by chronic disease on the propensity-matched cohort.
*p < 0.05; **p < 0.01; ***p < 0.01.
decrease the hospitalisation risk as well as costs. A nation-
wide implementation of guidelines such as elements used 
in the Chronic Care Model would improve the patient care 
even more, in terms of reduction of the disease severity or 
of avoiding the occurrence of comorbidity, and, further-
more, increase the cost-effectiveness.
Several strengths and limitations of our study have to 
be taken into account. The main strength is that the study 
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Table 6: Prediction of total healthcare costs by chronic disease on the propensity-matched cohort.
Ref., reference.
*p < 0.05; **p < 0.01; ***p < 0.01.
is based on a comprehensive healthcare claims data-
base, which covers a large population including patients 
with and without enrolment in integrated care models. 
Furthermore, this study is, to the best of our knowledge, 
the first one that investigated the impact of integrated 
care on quality indicators, in terms of disease-related 
hospitalisation, in patients with chronic diseases. The study 
also has several limitations. First, the number of patients 
with diabetes, cardiovascular diseases and respiratory 
illnesses may be each biased because clinical diagnoses 
(e.g., International Classification of Diseases, Version 10) 
from the outpatient setting were not available. However, 
Characteristic Healthcare costs (2013)
Diabetes Cardiovascular diseases Respiratory illnesses
Estimate 
CHF
95% confidence 
interval
Estimate 
CHF
95% confidence 
interval
Estimate 
CHF
95% confidence 
interval
Population characteristics
Gender
 Male Ref. Ref. Ref.
 Female −669.1*** −933.3 to −403.4 −412.2*** −499.0 to −325.8 284.0*** 166.3–402.3
Age group (years)
 18–44 Ref. Ref. Ref.
 45–54 −769.7** −1308.6 to −248.5 213.4** 59.9–364.6 220.4** 65.7–386.0
 55–64 −84.5 −632.4–438.5 431.2*** 284.9–573.9 1127.3*** 896.3–1373.2
 65–74 740.1** 190.0–1264.2 1242.4*** 1090.0–1391.7 1942.7*** 1642.0–2259.3
 75–84 1850.8*** 1252.8–2430.5 2300.5*** 2126.5–2473.1 2655.6*** 2230.1–3108.7
 ≥85 3379.8*** 2447.3–4370.3 3499.8*** 3226.6–3780.0 3368.2*** 4338.1–2517.0
Region of residence
 Lake Geneva Ref. Ref. Ref.
 Mittelland −555.5 −1138.5 to −10.6 −221.6* −436.4 to −17.0 −9.9 −209.0 to 180.6
 Northwest 188.5 −396.6 to 735.4 −262.4* −476.4 to −58.5 225.3* 11.7–435.9
 East 61.2 −535.0 to 622.1 −522.2*** −737.1 to −317.2 −251.9* −454.7 to −53.1
 Ticino 6705.3 −1399.7 to 25930.6 −1006.0 −2111.3 to 962.9 −944.6*** −506.6 to −1227.3
 Central 81.5 −740.1 to 948.0 −283.4* −548.6 to −17.4 −68.5 −326.1 to 217.4
 Zurich −96.4 −687.6 to 457.9 12.7 −202.7 to 218.2 145.4 −56.3 to 340.4
Health insurance status
 Care model
  Standard care model Ref. Ref. Ref.
  Integrated care model −777.8*** −1040.8 to −516.5 −441.3*** −527.3 to −355.6 −217.9*** −340.2 to −96.6
 Deductible
  Low (CHF 300/500) Ref. Ref. Ref.
  High (>CHF500) −344.2 −819.8 to 180.2 −1051.0*** −1150.7 to −950.0 −1266.0*** −1407.7 to −1127.0
Chronic disease score
 Level 1 (0–999) Ref. Ref. Ref.
 Level 2 (1000–2499) 642.2** 205.0–1060.8 861.4*** 749.1–974.9 1054.1*** 878.1–1238.6
 Level 3 (2500–4999) 2189.6*** 1698.1–2674.4 2019.8*** 1894.5–2146.2 1855.1*** 1628.2–2090.9
 Level 4 (5000–9999) 3750.8*** 3271.0–4216.0 4405.9*** 4251.7–4561.7 4820.9*** 4489.9–5161.5
 Level 5 (≥10,000) 10022.8*** 9322.7–10734.6 11260.3*** 10877.5–11654.4 11960.6*** 11197.6–12766.9
No. of hospitalised days (2011)
 0–3 days Ref. Ref. Ref.
 4–10 days 2809.3*** 2106.0–3575.4 1768.7*** 1506.2–2044.2 1644.4*** 1137.8–2223.9
 >10 days 6260.6*** 5206.3–7407.3 5030.8*** 4592.6–5489.8 7079.3*** 5810.9–8492.1
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diagnoses based on prescribed drugs are a valid proxy for 
clinical diagnoses and widely used in epidemiological 
and outcomes research to assess prevalence [18, 22]. For 
example, Cossman et al. [26] showed that prescription 
data are a useful proxy for disease-specific prevalence. 
Also, Chini et al. [27] concluded that drug data are a relia-
ble source for prevalence estimates of chronic conditions. 
Especially the use of prescriptions for anti-diabetic drugs 
and for chronic obstructive pulmonary disease drugs 
respectively could be used for a precise identification of 
patients with diabetes [28, 29] and patients with chronic 
obstructive pulmonary disease respectively [30] across 
large populations. Second, although using drug data as 
proxy diagnosis is a valid approach, it did not allow us 
to differentiate between particular diseases within each 
chronic disease group. Some elements (WHO Anatomical 
Therapeutic Chemical codes) could not be uniquely 
assigned to a given disease. Within the diabetes group, it 
was not possible to distinguish between diabetes type 1 
and type 2, within the group with cardiovascular diseases, 
between e.g. hypertension and other heart diseases, and 
within the respiratory illnesses group, between asthma 
and chronic obstructive pulmonary disease. Therefore, 
we were limited in the selection of chronic diseases 
and not able to consider the same categories of chronic 
patients as used in the study of Martínez-González 
et al. [4]. On the other side, we were able to identify three 
highly prevalent chronic diseases, where especially inte-
grated care might makes sense and can help to avoid 
worsening health or to prevent the development of (fur-
ther) comorbidities. Third, we are aware of the fact of 
potentially mismeasured or missing covariates such as 
variables indicating patients’ health status. Since medi-
cal diagnoses from the outpatient setting and further 
clinical parameters (e.g. laboratory values, body mass 
index, smoking) are not available in our data, we used 
drug-based diagnoses as a proxy for clinical diagnoses. 
For example, to measure patients’ comorbidity we used 
the Chronic Disease Score, a prescription-based morbidity 
measure. The included comorbidities may be biased 
because not all WHO Anatomical Therapeutic Chemical 
codes could be uniquely assigned to the treatment of a 
given disease. However, the Chronic Disease Score is the 
most frequently used and validated prescription-based 
method to determine chronic morbidity. Fourth, we did 
not distinguish between patients suffering from two or 
three chronic diseases simultaneously (diabetes, cardio-
vascular diseases, respiratory illnesses); thus, it is possible 
that for example a patient with diabetes belongs to the 
group with diabetes as well as to the group with cardio-
vascular diseases. However, we are quite confident that 
the allocation has not greatly influenced our results, since 
we adjusted for the comorbidity status (including diabe-
tes, cardio vascular disease, asthma/chronic obstructive 
pulmonary disease, respectively) in each of the analysis. 
Fifth, estimates of healthcare cost may be slightly too low 
because approximately 1.5% of the healthcare costs were 
not paid by the health insurer but directly by the patient 
(out-of-pocket).
Conclusion
These study findings contribute to the ongoing political 
discussion on the efficiency and also the further promo-
tion of integrated care models and provide valuable infor-
mation for an improved and more effective care of patients 
with chronic diseases. Integrated care should be seen as a 
key issue in healthcare quality and also more addressed in 
clinical, public health and health policy debates.
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Chronic disease Identification via ATC code Identification via ICD-10 code
Diabetes mellitus A10A, A10B, A10X E10–14
Cardiovascular 
diseases
B01AA, B01AC, B01AX, 
B01AE07, C01–03, C04A, 
C07–09
I10–I15, I20–I25, I26–I28, I47–I50, 
I61–I66, I67.0, I67.2, I67.4, I70–72, 
I73.9, I74
Respiratory illnesses R03 J41–46
Chronic disease Disease-related hospitalisation according ICD-10 classification
Diabetes mellitus E10–E14, I20–I25, I61–I66, I67.0, I67.2, I67.4, N17–N19, N08.3, H28.0, H36.0, I70, I79.2, G59.0, 
G63.2
Cardiovascular diseases I10–I15, I20–I28, I47–I50, I61–I66, I67.0, I67.2, I67.4, I70–I72, I73.9, I74
Respiratory illnesses J41–J47 (excl. J43.0)
Table A2: Classification of disease-related hospitalisations.
Table A1: Classification of patients with chronic diseases.
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Characteristic Patients with diabetes  
n = 36,532
Patients with cardiovascular 
diseases n = 186,986
Patients with respiratory 
illnesses n = 45,364
n (%) n (%) n (%)
Population characteristics (2012)
 Male 20052 (54.9) 85832 (45.9) 19447 (42.9)
 Mean age (sd) 67.2 (13.0) 68.2 (13.7) 58.9 (18.1)
Age group (years)
 18–44 2033 (5.6) 10455 (5.6) 10447 (23.0)
 45–54 3739 (10.2) 18727 (10.0) 6633 (14.6)
 55–64 7929 (21.7) 37159 (19.9) 8302 (18.3)
 65–74 11059 (30.3) 52590 (28.1) 9970 (22.0)
 75–84 9376 (25.7) 49459 (26.5) 7714 (17.0)
 ≥85 2396 (6.6) 18596 (10.0) 2298 (5.1)
Region of residence
 Lake Geneva 5465 (15.0) 23980 (12.8) 7203 (15.9)
 Mittelland 7208 (19.7) 35900 (19.2) 8601 (19.0)
 Northwest 5732 (15.7) 29611 (15.8) 7067 (15.6)
 East 4966 (13.6) 26843 (14.4) 5695 (12.6)
 Ticino 2539 (7.0) 12355 (6.6) 2879 (6.4)
 Central 2476 (6.8) 1337 (7.1) 3051 (6.7)
 Zurich 8146 (22.3) 44960 (24.0) 10868 (24.0)
Health insurance status
 Integrated care model 6263 (17.1) 35889 (19.2) 8749 (19.3)
Deductible
 High (>CHF500) 1775 (4.9) 17125 (9.2) 4951 (10.9)
 Low (CHF300/500) 34757 (94.1) 169861 (90.8) 40413 (89.1)
Chronic disease score (CDS)
 Mean CDS (sd) 7746 (6128.9) 5713 (5250.8) 6823 (6113.6)
 Level 1 (0–999) 1616 (4.4) 25742 (13.8) 6874 (15.2)
 Level 2 (1000–2499) 6880 (18.8) 30316 (16.2) 5922 (13.1)
 Level 3 (2500–4999) 5671 (15.5) 42423 (22.7) 8388 (18.5)
 Level 4 (5000–9999) 12394 (33.9) 59855 (32.0) 14736 (32.5)
 Level 5 (≥10000) 9971 (27.3) 28650 (15.3) 9444 (20.8)
Hospitalisation (2011) 7564 (20.7) 36747 (19.7) 8952 (19.7)
No. of hospitalised days (2011)
 Mean days (sd) 3.7 (13.8) 3.3 (12.8) 3.4 (13.3)
 0–3 days 30356 (83.1) 157966 (84.5) 38311 (84.5)
 4–10 days 2827 (7.7) 14028 (7.5) 3387 (7.5)
 >10 days 3349 (9.2) 14992 (8.0) 3666 (8.1)
Table A3: Patients characteristics by chronic disease before propensity-matching.
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 Summary of balance for all data
Means Treated Means Control SD Control Mean Diff eQQ Med eQQ Mean eQQ Max
Distance 0.2134 0.1627 0.0854 0.0507 0.0583 0.0507 0.0942
Age in years 67.1062 67.2526 13.0728 −0.1464 1 0.6077 3
CDS 7140.5362 7871.5302 6175.6716 −730.9941 775 741.2724 4399
Ded_high 0.0497 0.0484 0.2145 0.0013 0 0.0013 1
Geneva 0.065 0.1671 0.3731 −0.1021 0 0.1022 1
Mittelland 0.2071 0.1953 0.3964 0.0118 0 0.0118 1
Northwest 0.2612 0.1353 0.3421 0.1259 0 0.1258 1
East 0.2087 0.1209 0.326 0.0878 0 0.0878 1
Ticino 0.0008 0.0837 0.277 −0.0829 0 0.083 1
Central 0.0375 0.074 0.2618 −0.0365 0 0.0366 1
Zurich 0.2197 0.2237 0.4167 −0.004 0 0.004 1
No. of hospitalised 
days
3.243 3.8468 14.0993 −0.6038 0 0.6302 189
Summary of balance for matched data
Means Treated Means Control SD Control Mean Diff eQQ Med eQQ Mean eQQ Max
Distance 0.2134 0.2134 0.068 0 0 0 4.00E-04
Age in years 67.1062 67.0564 12.551 0.0498 0 0.5307 4.00E+00
CDS 7140.5362 6966.2443 5491.9203 174.2919 27 178.753 1.67E+04
Ded_high 0.0497 0.0474 0.2126 0.0022 0 0.0022 1.00E+00
Geneva 0.065 0.0664 0.249 −0.0014 0 0.0014 1.00E+00
Mittelland 0.2071 0.2058 0.4043 0.0013 0 0.0013 1.00E+00
Northwest 0.2612 0.2561 0.4365 0.0051 0 0.0051 1.00E+00
East 0.2087 0.2109 0.408 −0.0022 0 0.0022 1.00E+00
Ticino 0.0008 0.0008 0.0282 0 0 0 0.00E+00
Central 0.0375 0.0367 0.1881 0.0008 0 0.0008 1.00E+00
Zurich 0.2197 0.2232 0.4164 −0.0035 0 0.0035 1.00E+00
No. of hospitalised 
days
3.243 3.0838 12.0279 0.1592 0 0.179 2.50E+01
Percent Balance Improvement
Mean Diff. eQQ Med eQQ Mean eQQ Max
Distance 99.9961 99.998 99.9881 99.5987
Age in years 65.9777 100 12.6642 −33.3333
CDS 76.1569 96.5161 75.8857 −280.3137
Ded_high −73.2294 0 −75 0
Geneva 98.5928 0 98.5938 0
Mittelland 89.1814 0 89.1892 0
Northwest 95.9416 0 95.9391 0
East 97.4541 0 97.4545 0
Ticino 100 0 100 100
Central 97.8136 0 97.8166 0
Zurich 11.2542 0 12 0
No. of hospitalised 
days
73.6366 0 71.5987 86.7725
Table A4: Results showing the effectiveness of the propensity score matching among patients with diabetes.
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Figure A1: Propensity score before and after matching in patients with diabetes, cardiovascular diseases and respira-
tory illnesses.
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Figure A2: Distribution of propensity score in patients with diabetes, cardiovascular diseases and respiratory illnesses.
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Summary of balance for all data
Means Treated Means Control SD Control Mean Diff eQQ Med eQQ Mean eQQ Max
Distance 0.2337 0.182 0.0916 0.0517 0.0463 0.0517 0.1126
Age in years 67.9767 68.2904 13.7438 −0.3137 1 0.5933 3
CDS 5121.7543 5853.2708 5314.8696 −731.5165 723 731.95 8342
Ded_high 0.1071 0.0879 0.2831 0.0192 0 0.0192 1
Geneva 0.0506 0.1467 0.3538 −0.0961 0 0.0961 1
Mittelland 0.2045 0.189 0.3915 0.0155 0 0.0155 1
Northwest 0.2474 0.1372 0.3441 0.1102 0 0.1102 1
East 0.2091 0.128 0.3341 0.0812 0 0.0812 1
Ticino 0.0009 0.0816 0.2737 −0.0806 0 0.0806 1
Central 0.0382 0.0792 0.2701 −0.041 0 0.041 1
Zurich 0.2492 0.2384 0.4261 0.0109 0 0.0109 1
No. of hospitalised days 2.5988 3.4439 13.2891 −0.8451 0 0.8484 126
Summary of balance for matched data
Means Treated Means Control SD Control Mean Diff eQQ Med eQQ Mean eQQ Max
Distance 0.2337 0.2337 0.0662 0 0 0 0.0003
Age in years 67.9767 67.8084 13.5411 0.1683 0 0.4208 2
CDS 5121.7543 4974.4921 4685.194 147.2622 37 147.2622 9616
Ded_high 0.1071 0.104 0.3052 0.0031 0 0.0031 1
Geneva 0.0506 0.0516 0.2212 −0.001 0 0.001 1
Mittelland 0.2045 0.2063 0.4047 −0.0018 0 0.0018 1
Northwest 0.2474 0.2422 0.4284 0.0053 0 0.0053 1
East 0.2091 0.2083 0.4061 0.0008 0 0.0008 1
Ticino 0.0009 0.0009 0.0303 0 0 0 0
Central 0.0382 0.0378 0.1907 0.0004 0 0.0004 1
Zurich 0.2492 0.2529 0.4347 −0.0037 0 0.0037 1
No. of hospitalised days 2.5988 2.2298 8.943 0.369 0 0.369 92
Percent Balance Improvement
Mean Diff. eQQ Med eQQ Mean eQQ Max
Distance 99.999 100 99.9974 99.7426
Age in years 46.348 100 29.0753 33.3333
CDS 79.8689 94.8824 79.8808 −15.2721
Ded_high 83.6103 0 83.5994 0
Geneva 98.9564 0 98.9565 0
Mittelland 88.3166 0 88.3094 0
Northwest 95.2223 0 95.2224 0
East 98.9701 0 98.9701 0
Ticino 100 0 100 100
Central 99.1171 0 99.1174 0
Zurich 66.4629 0 66.4962 0
No. of hospitalised days 56.3321 0 56.5015 26.9841
Table A5: Results showing the effectiveness of the propensity score matching among patients with cardiovascular 
diseases.
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Summary of balance for all data
Means Treated Means Control SD Control Mean Diff eQQ Med eQQ Mean eQQ Max
Distance 0.225 0.1852 0.0811 0.0398 0.0311 0.0398 0.1281
Age in years 57.0702 59.2733 17.9302 −2.2031 1 2.2023 6
CDS 5843.5821 7056.6819 6215.7646 −1213.0998 1274 1214.3879 5390
Ded_high 0.1458 0.1004 0.3005 0.0455 0 0.0455 1
Geneva 0.1088 0.1707 0.3763 −0.0619 0 0.0619 1
Mittelland 0.2145 0.1836 0.3872 0.0309 0 0.0309 1
Northwest 0.2277 0.1386 0.3455 0.0891 0 0.089 1
East 0.1648 0.1162 0.3204 0.0487 0 0.0487 1
Ticino 0.0015 0.0783 0.2686 −0.0768 0 0.0768 1
Central 0.0405 0.0737 0.2612 −0.0332 0 0.0333 1
Zurich 0.2422 0.2389 0.4264 0.0033 0 0.0032 1
No. of 
hospitalised days
2.2707 3.6888 13.9077 −1.4181 0 1.427 86
Summary of balance for matched data
Means Treated Means Control SD Control Mean Diff eQQ Med eQQ Mean eQQ Max
Distance 0.225 0.225 0.0616 0 0 0 1.80E-03
Age in years 57.0702 56.3366 18.3466 0.7336 1 0.9846 4.00E+00
CDS 5843.5821 5560.6678 5161.4738 282.9143 118 282.9143 1.46E+04
Ded_high 0.1458 0.1423 0.3494 0.0035 0 0.0035 1.00E+00
Geneva 0.1088 0.1182 0.3228 −0.0094 0 0.0094 1.00E+00
Mittelland 0.2145 0.2161 0.4116 −0.0016 0 0.0016 1.00E+00
Northwest 0.2277 0.2203 0.4144 0.0074 0 0.0074 1.00E+00
East 0.1648 0.1561 0.363 0.0087 0 0.0087 1.00E+00
Ticino 0.0015 0.0015 0.0385 0 0 0 0.00E+00
Central 0.0405 0.0385 0.1925 0.0019 0 0.0019 1.00E+00
Zurich 0.2422 0.2493 0.4326 −0.0071 0 0.0071 1.00E+00
No. of 
hospitalised days
2.2707 2.0296 8.3597 0.2411 0 0.2525 6.50E+01
Percent Balance Improvement
Mean Diff. eQQ Med eQQ Mean eQQ Max
Distance 99.9864 99.9948 99.9755 98.6262
Age in years 66.7028 0 55.2938 33.3333
CDS 76.6784 90.7378 76.7031 −171.4286
Ded_high 92.2086 0 92.2111 0
Geneva 84.8611 0 84.8708 0
Mittelland 94.8211 0 94.8148 0
Northwest 91.6597 0 91.656 0
East 82.1497 0 82.1596 0
Ticino 100 0 100 100
Central 94.1467 0 94.1581 0
Zurich −117.8243 0 −121.4286 0
No. of 
hospitalised days
83.0015 0 82.3068 24.4186
Table A6: Results showing the effectiveness of the propensity score matching among patients with respiratory illnesses.
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